{
  "actions": [
    {
      "acted_at": "2020-09-08", 
      "action_code": "Intro-H", 
      "references": [], 
      "text": "Introduced in House", 
      "type": "action"
    }, 
    {
      "acted_at": "2020-09-08", 
      "action_code": "H11100", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2020-09-16", 
      "action_code": "B00100", 
      "references": [
        {
          "reference": "CR H4487", 
          "type": null
        }
      ], 
      "text": "Sponsor introductory remarks on measure.", 
      "type": "action"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr8190-116", 
  "bill_type": "hr", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }
  ], 
  "congress": "116", 
  "cosponsors": [
    {
      "bioguide_id": "S001204", 
      "district": "0", 
      "name": "San Nicolas, Michael F. Q.", 
      "original_cosponsor": false, 
      "sponsored_at": "2020-11-17", 
      "state": "GU", 
      "title": "Rep", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2020-09-08", 
  "number": "8190", 
  "official_title": "To amend the Public Health Service Act to deem any insulin that is determined by the Secretary to be biosimilar to the reference product to be interchangeable with the reference product, and for other purposes.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Biosimilar Insulin Access Act of 2020", 
  "sponsor": {
    "bioguide_id": "G000576", 
    "district": "6", 
    "name": "Grothman, Glenn", 
    "state": "WI", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2020-09-08", 
  "subjects": [
    "Blood and blood diseases", 
    "Competition and antitrust", 
    "Drug safety, medical device, and laboratory regulation", 
    "Drug therapy", 
    "Health", 
    "Health technology, devices, supplies", 
    "Intellectual property", 
    "Licensing and registrations", 
    "Prescription drugs"
  ], 
  "subjects_top_term": "Health", 
  "summary": null, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Biosimilar Insulin Access Act of 2020", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Biosimilar Insulin Access Act of 2020", 
      "type": "short"
    }, 
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Biosimilar Insulin Access Act of 2020", 
      "type": "display"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To amend the Public Health Service Act to deem any insulin that is determined by the Secretary to be biosimilar to the reference product to be interchangeable with the reference product, and for other purposes.", 
      "type": "official"
    }
  ], 
  "updated_at": "2020-11-18T08:15:28Z", 
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/hr/BILLSTATUS-116hr8190.xml"
}